We investigated the changes in cellular viability as well as the expression of the ERα-responsive downstream gene, progesterone receptor (PGR), in response to E2 or TAM, with treatments of GE and TSA alone or together in ERα-negative MDA-MB-231 breast cancer cells. This evidence concerns the gene ESR1 and breast carcinoma.